NASDAQ:FRLN Freeline Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Freeline Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.40 -0.11 (-0.67 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$16.37Now: $16.40▼$16.9350-Day Range N/A52-Week Range$15.25Now: $16.40▼$21.69Volume22,419 shsAverage Volume125,970 shsMarket Capitalization$425.10 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsHeadlinesSocial Media Freeline Therapeutics Holdings plc operates as a clinical-stage systemic adeno-associated virus (AAV)-based gene therapy company. Its advanced product candidate is FLT180a, a gene therapy product candidate that is being evaluated in a Phase 1/2 dose-finding clinical trials in adult males for the treatment of patients with moderate or severe hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Freeline Therapeutics. Previous Next 0.0 Community Rank Outperform VotesFreeline Therapeutics has received 1 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFreeline Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)MarketBeat's community ratings are surveys of what our community members think about Freeline Therapeutics and other stocks. Vote “Outperform” if you believe FRLN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FRLN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFreeline Therapeutics does not currently pay a dividend.Dividend GrowthFreeline Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Freeline Therapeutics insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Freeline Therapeutics are expected to grow in the coming year, from ($3.55) to ($2.94) per share. Previous Next Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.13 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FRLN Previous Symbol CUSIPN/A CIKN/A Webwww.freeline.life Phone44-14-3890-6870Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees200 Outstanding Shares25,921,000Market Cap$425.10 million Next Earnings DateN/A OptionableNot Optionable $16.40 -0.11 (-0.67 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive FRLN News and Ratings via Email Sign-up to receive the latest news and ratings for FRLN and its competitors with MarketBeat's FREE daily newsletter. Freeline Therapeutics (NASDAQ:FRLN) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Freeline Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Freeline Therapeutics. Who are some of Freeline Therapeutics' key competitors? Some companies that are related to Freeline Therapeutics include NanoString Technologies (NSTG), Cortexyme (CRTX), Sangamo Therapeutics (SGMO), Beam Therapeutics (BEAM), Kymera Therapeutics (KYMR), Coherus Biosciences (CHRS), Compugen (CGEN), Regenxbio (RGNX), Adaptimmune Therapeutics (ADAP), I-Mab (BDTX), Translate Bio (TBIO), Atara Biotherapeutics (ATRA), Alector (ALEC), Adverum Biotechnologies (ADVM) and Replimune Group (REPL). View all competitors. What other stocks do shareholders of Freeline Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE), CVS Health (CVS), Old Dominion Freight Line (ODFL), Shopify (SHOP), Zoom Video Communications (ZM), Zymeworks (ZYME), AbbVie (ABBV), American Airlines Group (AAL), Abbott Laboratories (ABT) and Advanced Micro Devices (AMD). Who are Freeline Therapeutics' key executives? Freeline Therapeutics' management team includes the following people: Ms. Theresa Marie Heggie, Chief Exec. Officer (Age 60)Mr. Brian M. Silver, CFO & Head of Corp. Devel. (Age 51)Dr. Amit Nathwani M.D., Ph.D., Chief Scientific Officer and Director (Age 60)Dr. Jan Thirkettle Ph.D., Chief Devel. Officer (Age 48)Dr. Gerard Short, Head of Clinical and Regulatory When did Freeline Therapeutics IPO? (FRLN) raised $126 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Freeline Therapeutics' stock symbol? Freeline Therapeutics trades on the NASDAQ under the ticker symbol "FRLN." When did Freeline Therapeutics' quiet period expire? Freeline Therapeutics' quiet period expired on Wednesday, September 16th. Freeline Therapeutics had issued 8,823,529 shares in its IPO on August 7th. The total size of the offering was $158,823,522 based on an initial share price of $18.00. During Freeline Therapeutics' quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Freeline Therapeutics? Shares of FRLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Freeline Therapeutics' stock price today? One share of FRLN stock can currently be purchased for approximately $16.40. How big of a company is Freeline Therapeutics? Freeline Therapeutics has a market capitalization of $425.10 million. Freeline Therapeutics employs 200 workers across the globe. What is Freeline Therapeutics' official website? The official website for Freeline Therapeutics is www.freeline.life. How can I contact Freeline Therapeutics? Freeline Therapeutics' mailing address is STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD STEVENAGE, HERTFORDSHIRE X0, SG12FX. The company can be reached via phone at 44-14-3890-6870 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
